Trial · NCT04171765
Results by group24
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 24
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Proportion of Participants With NASH Resolution on Overall Histopathological Reading Without Worsening of Fibrosis at Week 52 | Placebo | 16.7 | 95% Confidence Interval 0.00 to 54.82 | Percentage of Participants | |
| Proportion of Participants With NASH Resolution on Overall Histopathological Reading Without Worsening of Fibrosis at Week 52 | Fixed Dose 50 mg | 37.5 | 95% Confidence Interval 0.00 to 77.30 | Percentage of Participants | |
| Proportion of Participants With NASH Resolution on Overall Histopathological Reading Without Worsening of Fibrosis at Week 52 | Fixed Dose 75 mg | 14.3 | 95% Confidence Interval 0.00 to 47.35 | Percentage of Participants | |
| Proportion of Participants With NASH Resolution on Overall Histopathological Reading Without Worsening of Fibrosis at Week 52 | Fixed Dose 100 mg | 33.3 | 95% Confidence Interval 0.00 to 79.39 | Percentage of Participants | |
| Change From Baseline in Hepatic Fat Fraction as Assessed by Magnetic Resonance Imaging-Derived Proton Density Fat Fraction (MRI-PDFF) at Week 52 | Placebo | Baseline | 20.15 | Standard Deviation 6.35 | percentage of hepatic fat fraction |
| Change From Baseline in Hepatic Fat Fraction as Assessed by Magnetic Resonance Imaging-Derived Proton Density Fat Fraction (MRI-PDFF) at Week 52 | Fixed Dose 50 mg | Baseline | 20.67 | Standard Deviation 6.05 | percentage of hepatic fat fraction |
| Change From Baseline in Hepatic Fat Fraction as Assessed by Magnetic Resonance Imaging-Derived Proton Density Fat Fraction (MRI-PDFF) at Week 52 | Fixed Dose 75 mg | Baseline | 19.30 | Standard Deviation 3.99 | percentage of hepatic fat fraction |
| Change From Baseline in Hepatic Fat Fraction as Assessed by Magnetic Resonance Imaging-Derived Proton Density Fat Fraction (MRI-PDFF) at Week 52 | Fixed Dose 100 mg | Baseline | 18.12 | Standard Deviation 7.70 | percentage of hepatic fat fraction |
| Change From Baseline in Hepatic Fat Fraction as Assessed by Magnetic Resonance Imaging-Derived Proton Density Fat Fraction (MRI-PDFF) at Week 52 | Placebo | Week 16 change from baseline | -3.47 | Standard Deviation 2.28 | percentage of hepatic fat fraction |
| Change From Baseline in Hepatic Fat Fraction as Assessed by Magnetic Resonance Imaging-Derived Proton Density Fat Fraction (MRI-PDFF) at Week 52 | Fixed Dose 50 mg | Week 16 change from baseline | -8.20 | Standard Deviation 8.58 | percentage of hepatic fat fraction |
| Change From Baseline in Hepatic Fat Fraction as Assessed by Magnetic Resonance Imaging-Derived Proton Density Fat Fraction (MRI-PDFF) at Week 52 | Fixed Dose 75 mg | Week 16 change from baseline | -2.23 | Standard Deviation 9.05 | percentage of hepatic fat fraction |
| Change From Baseline in Hepatic Fat Fraction as Assessed by Magnetic Resonance Imaging-Derived Proton Density Fat Fraction (MRI-PDFF) at Week 52 | Fixed Dose 100 mg | Week 16 change from baseline | -10.25 | Standard Deviation 4.76 | percentage of hepatic fat fraction |
| Change From Baseline in Hepatic Fat Fraction as Assessed by Magnetic Resonance Imaging-Derived Proton Density Fat Fraction (MRI-PDFF) at Week 52 | Placebo | Week 52 change from baseline | -4.46 | Standard Deviation 6.23 | percentage of hepatic fat fraction |
| Change From Baseline in Hepatic Fat Fraction as Assessed by Magnetic Resonance Imaging-Derived Proton Density Fat Fraction (MRI-PDFF) at Week 52 | Fixed Dose 50 mg | Week 52 change from baseline | -2.50 | Standard Deviation 8.13 | percentage of hepatic fat fraction |
| Change From Baseline in Hepatic Fat Fraction as Assessed by Magnetic Resonance Imaging-Derived Proton Density Fat Fraction (MRI-PDFF) at Week 52 | Fixed Dose 75 mg | Week 52 change from baseline | -3.46 | Standard Deviation 11.57 | percentage of hepatic fat fraction |
| Change From Baseline in Hepatic Fat Fraction as Assessed by Magnetic Resonance Imaging-Derived Proton Density Fat Fraction (MRI-PDFF) at Week 52 | Fixed Dose 100 mg | Week 52 change from baseline | -3.53 | Standard Deviation 6.54 | percentage of hepatic fat fraction |
| Proportion of Participants With Improvement in Liver Histology From Baseline and no Worsening of Fibrosis at Week 52 | Placebo | 16.7 | 95% Confidence Interval 0.00 to 54.82 | Percentage of participants | |
| Proportion of Participants With Improvement in Liver Histology From Baseline and no Worsening of Fibrosis at Week 52 | Fixed Dose 50 mg | 37.5 | 95% Confidence Interval 0.00 to 77.30 | Percentage of participants | |
| Proportion of Participants With Improvement in Liver Histology From Baseline and no Worsening of Fibrosis at Week 52 | Fixed Dose 75 mg | 42.9 | 95% Confidence Interval 0.00 to 86.66 | Percentage of participants | |
| Proportion of Participants With Improvement in Liver Histology From Baseline and no Worsening of Fibrosis at Week 52 | Fixed Dose 100 mg | 33.3 | 95% Confidence Interval 0.00 to 79.39 | Percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04171765/results